Level Four Advisory Services LLC reduced its position in Shire PLC (NASDAQ:SHPG) by 36.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,739 shares of the biopharmaceutical company’s stock after selling 1,006 shares during the quarter. Level Four Advisory Services LLC’s holdings in Shire PLC were worth $304,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. American International Group Inc. grew its holdings in shares of Shire PLC by 1.2% during the 1st quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 54 shares during the last quarter. United Services Automobile Association grew its holdings in shares of Shire PLC by 4.1% during the 1st quarter. United Services Automobile Association now owns 16,225 shares of the biopharmaceutical company’s stock valued at $2,827,000 after purchasing an additional 641 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in shares of Shire PLC during the 1st quarter valued at approximately $3,515,000. Marshall Wace North America L.P. acquired a new stake in Shire PLC during the 1st quarter worth approximately $3,515,000. Finally, Mackenzie Financial Corp boosted its position in Shire PLC by 23.0% during the 1st quarter. Mackenzie Financial Corp now owns 3,425 shares of the biopharmaceutical company’s stock worth $597,000 after buying an additional 641 shares during the period. 19.23% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently commented on the stock. BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Barclays PLC downgraded shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Evercore ISI assumed coverage on shares of Shire PLC in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 price target on the stock. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $213.00 target price on shares of Shire PLC in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $219.33.
Shire PLC (NASDAQ:SHPG) traded up 2.84% on Friday, hitting $142.17. 2,091,441 shares of the company traded hands. The firm’s 50 day moving average price is $153.27 and its 200 day moving average price is $163.49. The firm has a market capitalization of $42.35 billion, a PE ratio of 63.61 and a beta of 1.63. Shire PLC has a 1-year low of $139.15 and a 1-year high of $192.64.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, topping the consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.72 billion. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Shire PLC’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period last year, the company earned $3.17 earnings per share. Equities research analysts predict that Shire PLC will post $14.92 EPS for the current fiscal year.
The firm also recently disclosed a semiannual dividend, which was paid on Friday, October 20th. Shareholders of record on Friday, September 8th were issued a $0.1527 dividend. This represents a yield of 0.21%. The ex-dividend date was Thursday, September 7th. Shire PLC’s payout ratio is currently 41.07%.
ILLEGAL ACTIVITY NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/level-four-advisory-services-llc-sells-1006-shares-of-shire-plc-shpg.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.